Novel ocular antihypertensive compounds in clinical trials

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 667-677

  Chen, June ^a   Runyan, Stephen A ^a   Robinson, Michael R ^a  

^a ALLERGAN INC   (United States)

Author keywords

Antihypertensive; Aqueous humor dynamics; Clinical trials; Drug development; Glaucoma progression; Intraocular pressure

Indexed keywords

6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ACTIN; ADENOSINE DERIVATIVE; AGENTS ACTING ON THE EYE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIGLAUCOMA AGENT; AR 102; AR 12286; ATL 313; BIMATOPROST; CANNABINOID RECEPTOR AGONIST; INO 8875; INS 115644; INS 117548; K 115; LATANOPROST; LATRUNCULIN B; OLMESARTAN; OPA 6566; PLACEBO; RHO KINASE; RHO KINASE INHIBITOR; SAD 448; SEROTONIN ANTAGONIST; SYL 040012; TAPRENEPAG ISOPROPYL ESTER; TIMOLOL; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG; Y 39983;

CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; CORNEA PERMEABILITY; CORNEA THICKNESS; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EYE BURN; EYE DISEASE; EYE IRRITATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; NONHUMAN; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PHOTOPHOBIA; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SUSTAINED DRUG RELEASE; VASCULAR DISEASE;

EID: 79958807531     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S15971     Document Type: Review

References (96)

1. Desai P V, Caprioli J. The treatment of normal-tension glaucoma. Prog Brain Res. 2008;173:195-210.
2. Shields MB. Normal-tension glaucoma: is it different from primary open-angle glaucoma? Curr Opin Ophthalmol. 2008;19(2):85-88.
3. Fautsch M P, Johnson DH. Aqueous humor outflow: what do we know? Where will it lead us? Invest Ophthalmol Vis Sci. 2006;47(10): 4181-4187.
4. Alm A, Nilsson S F. Uveoscleral outflow - a review. Exp Eye Res. 2009;88(4):760-768.
5. Bahrami H. Causal inference in primary open angle glaucoma: specific discussion on intraocular pressure. Ophthalmic Epidemiol. 2006;13(4): 283-289.
6. Gabelt BT, Kaufman PL. Changes in aqueous humor dynamics with age and glaucoma. Prog Retin Eye Res. 2005;24(5):612-637.
7. Johnson M. What controls aqueous humour outfow resistance? Exp Eye Res. 2006;82(4):545-557.
8. Pache M, Flammer J. A sick eye in a sick body? Systemic fndings in patients with primary open-angle glaucoma. Surv Ophthalmol. 2006; 51(3):179-212.
9. Tektas OY, Lütjen-Drecoll E. Structural changes of the trabe-cular meshwork in different kinds of glaucoma. Exp Eye Res. 2009; 88(4):769-775.
10. Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. N Engl J Med. 2009;360(11):1113-1124.
11. Wierzbowska J, Robaszkiewicz J, Figurska M, Stankiewicz A. Future possibilities in glaucoma therapy. Med Sci Monit. 2010;16(11): RA252-RA259.
12. Peeters A, Webers CA, Prins MH, Zeegers M P, Hendrikse F, Schouten JS. Quantifying the effect of intraocular pressure reduction on the occurrence of glaucoma. Acta Ophthalmol. 2010;88(1):5-11.
13. Susanna R Jr. Unpredictability of glaucoma progression. Curr Med Res Opin. 2009;25(9):2167-2177.
14. Weinreb RN, Kaufman PL. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci. 2009;50(4):1497-1505.
15. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specifc genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806-811.
16. Qiu S, Adema CM, Lane T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 2005;33(6):1834-1847.
17. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426-433.
18. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492-503.
19. Lim KS, Nau CB, O'Byrne MM, et al. Mechanism of action of bimato-prost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmolog y. 2008;115(5):790-795.
20. Alexander SPH, Mathie A, Peters JA. Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol. 2009;(158 Suppl 1):S1-S254.
21. Nilsson SF, Drecoll E, Lütjen-Drecoll E, et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci. 2006;47(9): 4042-4049.
22. Schachar RA, Raber S, Courtney R, Zhang M, Bosworth C. Dose-escalating, double-masked, vehicle-controlled trial of the IOP-reducing effect of the EP2 agonist PF-04217329. Invest Ophthalmol Vis Sci. 2010;51: Association for Research in Vision and Ophtahlmology (ARVO) E-Abstract 175.
23. Schachar RA, Raber S, Zhang MH, Bosworth CF. A randomized, multicenter clinical trial of the IOP-reducing effect of the EP2 agonist taprenepag isopropyl (PF-04217329). American Academy of Ophthalmology. 2010;Abstract PO373.
24. Kowing D, Messer D, Slagle S, Wasik A; V-POAG Study Group. Programs to optimize adherence in glaucoma. Optometry. 2010;81(7):339-350.
25. Pollard TD, Cooper JA. Actin, a central player in cell shape and movement. Science. 2009;326(5957):1208-1212.
26. Groweiss A, Shmueli U, Kashman Y. Marine toxins of Latrunculia magnifca. J Org Chem. 1983;48:3512-3516.
27. Coué M, Brenner SL, Spector I, Korn ED. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987;213(2):316-318.
28. Spector I, Braet F, Shochet NR, Bubb MR. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc Res Tech. 1999;47(1):18-37.
29. Wakatsuki T, Schwab B, Thompson NC, Elson EL. Effects of cytocha-lasin D and latrunculin B on mechanical properties of cells. J Cell Sci. 2001;114(Pt 5):1025-1036.
30. Peterson JA, Tian B, McLaren J W, Hubbard WC, Geiger B, Kaufman PL. Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest Ophthalmol Vis Sci. 2000; 41(7):1749-1758.
31. Okka M, Tian B, Kaufman PL. Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. Arch Ophthalmol. 2004;122(10):1482-1488. Comment in: Arch Ophthalmol. 2005 Oct;123(10):1456-1457; author reply 1457.
32. Sabanay I, Tian B, Gabelt BT, Geiger B, Kaufman PL. Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys. Exp Eye Res. 2006;82(2):236-246.
33. Ethier CR, Read AT, Chan DW. Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes. Invest Ophthalmol Vis Sci. 2006;47(5):1991-1998.
34. Ritch R, Schiewe M, Zink RC, et al. Latrunculin B (INS115644) reduces intraocular pressure (IOP) in ocular hypertension (OHT) and primary open angle glaucoma (POAG). Invest Ophthalmol Vis Sci. 2010;51: ARVO E-Abstract and Poster 6432.
35. Okka M, Tian B, Kaufman PL. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys. Trans Am Ophthalmol Soc. 2004;102:251-259.
36. Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the acto-myosin system in regulating trabecular fuid outflow. Exp Eye Res. 2009;88(4):713-717.
37. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4(6):446-456.
38. Hall A. Rho GTPases and the control of cell behaviour. Biochem Soc Trans. 2005;33(Pt 5):891-895.
39. Olson M F. Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008;20(2):242-248.
40. Fukiage C, Mizutani K, Kawamoto Y, Azuma M, Shearer TR. Involvement of phosphorylation of myosin phosphatase by ROCK in trabecular meshwork and ciliary muscle contraction. Biochem Biophys Res Commun. 2001;288(2):296-300.
41. Nakajima E, Nakajima T, Minagawa Y, Shearer TR, Azuma M. Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outfow in monkey and human eyes. J Pharm Sci. 2005;94(4):701-708.
42. Rao V P, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Bio Drugs. 2007;21(3):167-177.
43. Inoue T, Pecen P, Maddala R, et al. Characterization of cytoskeleton-enriched protein fraction of the trabecular meshwork and ciliary muscle cells. Invest Ophthalmol Vis Sci. 2010;51(12):6461-6471.
44. Rao P V, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specifc inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42(5):1029-1037. Erratum in: Invest Ophthalmol Vis Sci. 2001;42(8):1690.
45. Koga T, Koga T, Awai M, Tsutsui J, Yue BY, Tanihara H. Rho-associated protein kinase inhibitor, Y-27632, induces alterations in adhesion, contraction and motility in cultured human trabecular meshwork cells. Exp Eye Res. 2006;82(3):362-370.
46. Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4(5):387-398.
47. Jacobs M, Hayakawa K, Swenson L, et al. The structure of dimeric ROCK I reveals the mechanism for ligand selectivity. J Biol Chem. 2006;281(1):260-268.
48. Tamura M, Nakao H, Yoshizaki H, et al. Development of specifc Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005;1754(1-2):245-252.
49. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci. 2007;48(7):3216-3222.
50. DeLong MA, Sturdivant JM, Royalty SM, et al. Discovery and in vitro SAR of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. From Abstracts of Papers, 240th American Chemical Society National Meeting, Boston, MA, US, August 22-26, 2010 (2010), MEDI-307. Database: CAPLUS.
51. McCallister E. Rho King glaucoma. Bio Century, The Bernstein Report on BioBusiness. 2009 Oct 26;Page A8. http://www.biocentury.com.
52. Wang R-F, Serle JB, Kopczynski C. Effect of 0.6% AR-12286 on aqueous humor dynamics in 6 normotensive monkey eyes. Invest Ophthalmol Vis Sci. 2009;50:ARVO E-Abstract 1465.
53. Williams RD, Novack GD, van Haarlem T, Kopczynski C, and AR-12286 Phase 2a Study Group. Ocular hypotensive effcacy and safety of the Rho kinase inhibitor AR-12286 in patients with elevated intraocular pressure. Invest Ophthalmol Vis Sci. 2010;51: ARVO E-Abstract 1633.
54. Mizuno K, Koide T, Fujieda Y, et al. Ocular hypotensive and neu-roprotective effects of K-115, a novel Rho-kinase inhibitor. Invest Ophthalmol Vis Sci. 2007;48:ARVO E-Abstract 4805.
55. Tanihara H, Inatani M, Honjo M, Tokushige H, Azuma J, Araie M. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126(3):309-315.
56. Fredholm BB, Ijzerman A P, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classif-cation of adenosine receptors. Pharmacol Rev. 2001;53(4):527-552.
57. Fredholm BB. Adenosine receptors as drug targets. Exp Cell Res. 2010;316(8):1284-1288.
58. Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp Eye Res. 1997;64(6):979-989.
59. Fleischhauer JC, Mitchell CH, Stamer WD, Karl MO, Peterson-Yantorno K, Civan MM. Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport. J Membr Biol. 2003;193(2):121-136.
60. 6-cyclohexyladenosine. Invest Ophthalmol Vis Sci. 2005;46(10):3795-3799.
61. Husain S, Shearer T W, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther. 2007;320(1): 258-265.
62. Karl MO, Peterson-Yantorno K, Civan MM. Cell-specific differential modulation of human trabecular meshwork cells by selective adenosine receptor agonists. Exp Eye Res. 2007;84(1):126-134.
63. Mitchell CH, Peterson-Yantorno K, Carré DA, et al. A3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells. Am J Physiol. 1999;276(3):C659-C666.
64. Do C W, Civan MM. Swelling-activated chloride channels in aqueous humour formation: on the one side and the other. Acta Physiol. 2006;187(1-2):345-352.
65. Kim N, Crosson C, Supuran C, et al. INO-8875, an adenosine A1 agonist, in development for open-angle glaucoma reduces IOP in three rabbit models. Invest Ophthalmol Vis Sci. 2009;50: ARVO E-Abstract 4061.
66. Kim N, Crosson C, Lam T, et al. INO-8875, an adenosine A1 agonist, lowers intraocular pressure through the conventional outfow pathway. Invest Ophthalmol Vis Sci. 2010;51: ARVO E-Abstract 3238.
67. Webb RL, Sills MA, Chovan J P, Peppard J V, Francis JE. Development of tolerance to the antihypertensive effects of highly selective adenosine A2a agonists upon chronic administration. J Pharmacol Exp Ther. 1993;267(1):287-295.
68. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal. 2002;14(2):99-108.
69. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5(3):247-264.
70. Avni I, Garzozi HJ, Barequet IS, et al. Treatment of dry eye syndrome with orally administered CF101: data from a Phase 2 clinical trial. Ophthalmology. 2010;117(7):1287-1293.
71. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. 2008;117(1):123-140.
72. Okamura T, Kurogi Y, Hashimoto K, et al. Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma. Bioorg Med Chem Lett. 2004;14(14): 3775-3779.
73. Vaajanen A, Luhtala S, Oksala O, Vapaatalo H. Does the renin-angio-tensin system also regulate intra-ocular pressure? Ann Med. 2008;40(6): 418-427.
74. Fletcher EL, Phipps JA, Ward MM, Vessey KA, Wilkinson-Berka JL. The renin-angiotensin system in retinal health and disease: Its infuence on neurons, glia and the vasculature. Prog Retin Eye Res. 2010;29(4): 284-311.
75. Rao P V, Deng P, Sasaki Y, Epstein DL. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outfow facility. Exp Eye Res. 2005;80(2):197-206.
76. Cullinane AB, Leung PS, Ortego J, Coca-Prados M, Harvey BJ. Renin-angiotensin system expression and secretory function in cultured human ciliary body non-pigmented epithelium. Br J Ophthalmol. 2002;86(6):676-683.
77. Wang RF, Podos SM, Mittag TW, Yokoyoma T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2005;80(5):629-632.
78. Stapp L, Fan S, Toris CB. The effects of the angiotensin II receptor antagonist, olmesartan, on aqueous humor dynamics in monkeys. Invest Ophthalmol Vis Sci. 2008;49: ARVO E-Abstract 353.
79. Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol. 2004;88(5):708-713.
80. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389-462.
81. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4(8):1614-1648.
82. Chien F Y, Wang RF, Mittag T W, Podos SM. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch Ophthalmol. 2003;121(1):87-90.
83. Ya o BB, Hsieh GC, Frost JM, et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol. 2008;153(2): 390-401.
84. Stamer WD, Golightly S F, Hosohata Y, et al. Cannabinoid CB1 receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol. 2001;431(3): 277-286.
85. Stumpff F, Boxberger M, Krauss A, et al. Stimulation of cannabi-noid CB1 and prostanoid EP2 receptors opens BKCa channels and relaxes ocular trabecular meshwork. Exp Eye Res. 2005;80(5): 697-708.
86. Ramer R, Hinz B. Cyclooxygenase-2 and tissue inhibitor of matrix metalloproteinases-1 confer the antimigratory effect of cannabinoids on human trabecular meshwork cells. Biochem Pharmacol. 2010;80(6): 846-857.
87. McCallister E, Bernstein K. The eyes have it. BioCentury, The Bernstein Report on BioBusiness, 2008 Sept 29;page 1-8. http://www.biocen-tury.com.
88. ®): clinical study. Invest Ophthalmol Vis Sci. 2010;51: ARVO E-Abstract 988.
89. Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5): 1614-1641.
90. Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol. 2008;6(4):293-310.
91. Gabelt BT, Millar CJ, Kiland JA, Peterson JA, Seeman JL, Kaufman PL. Effects of serotonergic compounds on aqueous humor dynamics in monkeys. Curr Eye Res. 2001;23(2):120-127.
92. May JA, McLaughlin MA, Sharif NA, Hellberg MR, Dean TR. Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306(1):301-309.
93. Gabelt BT, Okka M, Dean TR, Kaufman PL. Aqueous humor dynamics in monkeys after topical R-DOI. Invest Ophthalmol Vis Sci. 2005;46(12):4691-4696.
94. Allen JA, Yadav PN, Roth BL. Insights into the regulation of 5-HT2A serotonin receptors by scaffolding proteins and kinases. Neuropharmacolog y. 2008;55(6):961-968.
95. Gray JA, Roth BL. Paradoxical traffcking and regulation of 5-HT2A receptors by agonists and antagonists. Brain Res Bull. 2001;56(5): 441-451.
96. Bunch TJ, Seeman JL, Gabelt BT, et al. BVT.28949 as a potential ocular hypotensive agent in monkeys. Invest Ophthalmol Vis Sci. 2004;45: ARVO E-Abstract 5040.